Short-term changes in renal function after repeated intravitreal bevacizumab in patients with diabetic macular edema: a preliminary study
Öz
Purpose: The aim of this study was to evaluate short-term changes in renal function after repeated intravitreal bevacizumab injections in treatment-naive patients with diabetic macular edema (DME) in a preliminary retrospective cohort.
Materials and Methods: This preliminary retrospective observational study included 100 patients with DME who received at least three monthly intravitreal bevacizumab injections (1.25 mg/0.05 mL) between 2023 and 2026. Serum urea and creatinine concentrations and estimated glomerular filtration rate (eGFR), calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation recorded by the institutional laboratory, were obtained before the first injection and within one month after the final injection.
Results: The mean age was 68.07 ± 9.43 years, 52 patients (52.0%) were female, and the mean number of injections was 4.03 ± 2.72. Mean eGFR decreased from 76.76 ± 21.67 to 71.88 ± 22.71 mL/min/1.73 m². Serum urea increased from 40.86 ± 16.23 to 45.79 ± 18.58 mg/dL, and serum creatinine increased from 0.96 ± 0.35 to 1.02 ± 0.39 mg/dL. Injection number was not significantly correlated with either baseline or follow-up eGFR.
Conclusions: In this preliminary study, repeated intravitreal bevacizumab treatment was temporally associated with modest short-term changes in renal function parameters.
Anahtar Kelimeler
bevacizumab, Diabetic Makula Edema, Glomerular Filtration Rate, İntravitreal İnjection, Vascular Endothelial Growth Factor
Etik Beyan
The study was approved by the Clinical Research Ethics Committee of Kırşehir Ahi Evran University (2026-11/187).
Kaynakça
- Virgili G, Parravano M, Evans JR, Gordon I, Lucenteforte E. Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis. Cochrane Database Syst Rev. 2017;6:CD007419.
- Pham B, Thomas SM, Lillie E, et al. Anti-vascular endothelial growth factor treatment for retinal conditions: a systematic review and meta-analysis. BMJ Open. 2019;9:e022031.
- Yilmaz M, Citirik M, Rahmanlar H, Alkan A, Gursoz H. Off-label uses of aflibercept, ranibizumab and dexamethasone implant for diabetic retinopathy in Turkey. Rom J Ophthalmol. 2022;66:304-9.
- Hirano T, Toriyama Y, Iesato Y, Imai A, Murata T. Changes in plasma vascular endothelial growth factor level after intravitreal injection of bevacizumab, aflibercept, or ranibizumab for diabetic macular edema. Retina. 2018;38:1801-8.
- Camp DA, Price DA, Neiweem AE, Jusufbegovic D. Effects of intravitreal bevacizumab therapy on glomerular filtration rates in patients treated for proliferative diabetic retinopathy. Retina. 2022;42:1926-30.
- Prieto del Cura M, Carballes MJC, Sastre-Ibanez M. Risk of renal damage associated with intravitreal anti-VEGF therapy for diabetic macular edema in routine clinical practice. Indian J Ophthalmol. 2023;71:3091-95.
- Rivero M, Fernandez-Vidal M, Sandino J, et al. Effect of intravitreal anti-endothelial growth factor agents on renal function in patients with diabetes mellitus. Kidney Int Rep. 2024;9:1397-1405.
- Cai CX, Nishimura A, Bowring MG, et al. Similar risk of kidney failure among patients with blinding diseases who receive ranibizumab, aflibercept, and bevacizumab: an OHDSI Network Study. Ophthalmol Retina. 2024;8:733-43.
- Wang L, Jin L, Wang W, et al. Association of renal function with diabetic retinopathy and macular oedema among Chinese patients with type 2 diabetes mellitus. Eye. 2023;37:1538-44.
- Debourdeau E, Medard R, Chamard C, et al. Does HbA1c level or glomerular filtration rate affect the clinical response to vascular endothelial growth factor therapy in diabetic macular edema? A real-life experience. Ophthalmol Ther. 2023;12:2657-70.
